Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2019-03-14 | AMPH | Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | Pres, GC | S - Sale+OE | $20.35 | -32,336 | 176,028 | -16% | -$657,930 | |||||
| D | 2019-03-15 | PFE | Pfizer Inc | Johnson Rady A | EVP | S - Sale+OE | $41.13 | -8,700 | 64,960 | -12% | -$357,831 | |||||
2019-03-14 | BGNE | Beigene, Ltd. | Glazer Donald W. | Dir | S - Sale | $136.10 | -14,973 | 4,145,029 | 0% | -$2,037,825 | ||||||
2019-03-15 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Dir | P - Purchase | $4.15 | +24,000 | 24,000 | New | +$99,600 | ||||||
2019-03-15 | OCUL | Ocular Therapeutix, Inc | Goldstein Michael H. | Chief Medical Officer | P - Purchase | $4.15 | +10,000 | 13,686 | +271% | +$41,500 | ||||||
| ADM | 2019-03-14 | VCNX | Vaccinex, Inc. | Friedberg Albert | Dir, 10% | P - Purchase | $3.98 | +2,000 | 5,850,990 | 0% | +$7,960 | |||||
| M | 2019-03-14 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $12.26 | -11,626 | 2,829,403 | 0% | -$142,561 | |||||
| DM | 2019-03-14 | VCNX | Vaccinex, Inc. | Friedberg Albert | Dir, 10% | P - Purchase | $3.98 | +2,000 | 5,850,990 | 0% | +$7,960 | |||||
2019-03-18 | XCUR | Exicure, Inc. | Mirkin Chad A. | Dir, 10% | P - Purchase | $2.40 | +1,000 | 11,300,260 | 0% | +$2,400 | ||||||
2019-03-18 | ATHX | Athersys, Inc / New | Lehmann William Jr | Pres, COO | S - Sale | $1.53 | -15,000 | 453,751 | -3% | -$22,947 | ||||||
| M | 2019-02-21 | ALKS | Alkermes Plc. | Wysenski Nancy | Dir | P - Purchase | $33.09 | +4,302 | 4,302 | New | +$142,340 | |||||
2019-03-14 | CLVS | Clovis Oncology, Inc. | Blair James C | Dir | S - Sale | $27.79 | -17,056 | 23,544 | -42% | -$473,986 | ||||||
| D | 2019-03-18 | ATNX | Athenex, Inc. | Lau Johnson Yiu Nam | CEO, COB, 10% | P - Purchase | $12.52 | +4,000 | 3,883,944 | 0% | +$50,080 | |||||
| DM | 2019-03-14 | VCNX | Vaccinex, Inc. | Friedberg Albert | Dir, 10% | P - Purchase | $3.98 | +2,000 | 5,850,990 | 0% | +$7,960 | |||||
| DM | 2019-03-14 | ATNX | Athenex, Inc. | Trainor-Degirolamo Sheldon | Dir | S - Sale+OE | $11.77 | -54,085 | 611,333 | -8% | -$636,581 | |||||
| D | 2019-03-14 | ZTS | Zoetis Inc. | Lewis Clinton A. Jr. | EVP | S - Sale+OE | $96.54 | -6,125 | 50,917 | -11% | -$591,308 | |||||
2019-03-14 | NATR | Natures Sunshine Products Inc | Wynnefield Partners Small Cap Value LP | 10% | P - Purchase | $10.44 | +1,666 | 2,219,375 | 0% | +$17,385 | ||||||
| M | 2019-03-14 | ATHX | Athersys, Inc / New | Harrington John J | Exec Vice Pres, CSO | S - Sale | $1.55 | -15,000 | 619,666 | -2% | -$23,288 | |||||
2019-03-15 | VERU | Veru Inc. | Fisch Harry | Dir, 10% | P - Purchase | $1.47 | +3,000 | 8,075,121 | 0% | +$4,410 | ||||||
2019-03-15 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Hochman David P | Dir | P - Purchase | $6.98 | +2,000 | 704,400 | 0% | +$13,958 | ||||||
2019-03-15 | CLSD | Clearside Biomedical, Inc. | Deignan Charles A. | CFO | P - Purchase | $1.36 | +10,000 | 76,356 | +15% | +$13,600 | ||||||
2019-03-14 | ASRT | Assertio Therapeutics, Inc | Bukofzer Stan | SVP, Chf Scitfc, Tech Officer | P - Purchase | $4.13 | +5,000 | 5,000 | New | +$20,658 | ||||||
2019-03-14 | ASRT | Assertio Therapeutics, Inc | Peisert Daniel A. | SVP, CFO | P - Purchase | $4.18 | +6,000 | 21,356 | +39% | +$25,069 | ||||||
| D | 2019-03-13 | GWPH | Gw Pharmaceuticals Plc | Mackey Catherine J | Dir | S - Sale+OE | $14.39 | -888 | 19,284 | -4% | -$12,778 | |||||
| M | 2019-03-11 | STML | Stemline Therapeutics Inc | Bergstein Ivan | CEO | S - Sale | $11.11 | -57,224 | 2,662,127 | -2% | -$635,630 | |||||
| M | 2019-03-11 | STML | Stemline Therapeutics Inc | Hoberman Kenneth | COO | S - Sale | $11.11 | -26,082 | 755,696 | -3% | -$289,702 | |||||
| M | 2019-03-11 | STML | Stemline Therapeutics Inc | Gionco David | Chief Accounting Officer | S - Sale | $11.11 | -14,022 | 224,938 | -6% | -$155,753 | |||||
2019-03-13 | DRRX | Durect Corp | Saxe Jon S | Dir | P - Purchase | $0.82 | +3,700 | 72,810 | +5% | +$3,021 | ||||||
2019-03-13 | DRRX | Durect Corp | Saxe Jon S | Dir | P - Purchase | $0.82 | +21,300 | 41,300 | +107% | +$17,480 | ||||||
2019-03-14 | KALV | Kalvista Pharmaceuticals, Inc. | Crockett Thomas Andrew | CEO | S - Sale | $30.16 | -3,000 | 268,510 | -1% | -$90,484 | ||||||
2019-03-14 | ESPR | Esperion Therapeutics, Inc. | Biotech Target N V | 10% | P - Purchase | $49.89 | +50,000 | 3,522,964 | +1% | +$2,494,355 | ||||||
2019-03-14 | FGEN | Fibrogen Inc | Yu K Peony | Chief Medical Officer | S - Sale | $56.30 | -9,145 | 182,440 | -5% | -$514,864 | ||||||
2019-03-14 | ABBV | Abbvie Inc. | Schumacher Laura J | Vice COB | S - Sale | $80.00 | -25,000 | 139,838 | -15% | -$2,000,000 | ||||||
| M | 2019-03-13 | ALRN | Aileron Therapeutics Inc | Novartis Bioventures Ltd | 10% | S - Sale | $2.06 | -190,338 | 2,206,544 | -8% | -$391,445 | |||||
| M | 2019-03-13 | ZGNX | Zogenix, Inc. | Hawley Roger | Dir | S - Sale | $52.99 | -60,000 | 10,575 | -85% | -$3,179,476 | |||||
| D | 2019-03-15 | ATNX | Athenex, Inc. | Lau Johnson Yiu Nam | CEO, COB, 10% | P - Purchase | $11.77 | +12,000 | 3,879,944 | 0% | +$141,240 | |||||
| D | 2019-03-13 | CARA | Cara Therapeutics, Inc. | Mohindru Mani | CFO, Chief Strategy Officer | S - Sale+OE | $19.12 | -16,041 | 8,026 | -67% | -$306,704 | |||||
| D | 2019-03-13 | TCDA | Tricida, Inc. | Otto Dawn Parsell | SVP, Clinical Development | S - Sale+OE | $25.00 | -2,000 | 0 | -100% | -$50,000 | |||||
| DM | 2019-03-13 | TCDA | Tricida, Inc. | Lockey Claire | Chief Dev. Officer, SVP | S - Sale+OE | $25.01 | -13,494 | 0 | -100% | -$337,500 | |||||
| M | 2019-03-13 | RYTM | Rhythm Pharmaceuticals, Inc. | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.06 | -9,288 | 516,632 | -2% | -$279,182 | |||||
| M | 2019-03-13 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, CFO, MD | S - Sale | $63.96 | -67,376 | 423,230 | -14% | -$4,309,297 | |||||
2019-03-13 | LGND | Ligand Pharmaceuticals Inc | Aryeh Jason | Dir | P - Purchase | $112.51 | +202 | 115,737 | 0% | +$22,727 | ||||||
2019-03-13 | LGND | Ligand Pharmaceuticals Inc | Higgins John L | CEO | P - Purchase | $114.29 | +2,500 | 141,399 | +2% | +$285,725 | ||||||
2019-03-15 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Jenkins John Kenneth | Dir | P - Purchase | $6.98 | +1,000 | 1,000 | New | +$6,978 | ||||||
2019-03-14 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Millian Craig Stuart | Chief Commercial Officer | P - Purchase | $6.85 | +5,000 | 5,000 | New | +$34,259 | ||||||
2019-03-14 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $2.45 | +250,000 | 212,829,633 | 0% | +$612,918 | ||||||
| M | 2019-03-12 | SYRS | Syros Pharmaceuticals, Inc. | Arch Venture Fund Vii, L.P. | 10% | S - Sale | $7.83 | -167,503 | 4,305,051 | -4% | -$1,312,380 | |||||
| D | 2019-03-14 | ALKS | Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | S - Sale+OE | $33.05 | -25,000 | 185,122 | -12% | -$826,373 | |||||
| DM | 2019-03-12 | ALKS | Alkermes Plc. | Pops Richard F | Dir, CEO, Alkermes plc | S - Sale+OE | $33.32 | -60,000 | 716,433 | -8% | -$1,998,932 | |||||
| D | 2019-03-13 | MRK | Merck & Co., Inc. | Frazier Kenneth C | COB, Pres, CEO | S - Sale+OE | $82.00 | -18,725 | 801,725 | -2% | -$1,535,454 | |||||
| D | 2019-03-12 | IONS | Ionis Pharmaceuticals Inc | Parshall B Lynne | Dir | S - Sale+OE | $75.00 | -8,334 | 52,677 | -14% | -$625,050 | |||||
2019-03-13 | ELAN | Elanco Animal Health Inc | Hoover R David | Dir | P - Purchase | $31.43 | +20,000 | 32,716 | +157% | +$628,586 | ||||||
2019-01-23 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $0.70 | +142,857 | 7,529,020 | +2% | +$100,000 | ||||||
2019-01-23 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $0.70 | +142,857 | 7,529,020 | +2% | +$100,000 | ||||||
| D | 2019-03-12 | BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Tilton John | Chief Commercial Officer | S - Sale+OE | $50.11 | -10,000 | 1,614 | -86% | -$501,100 | |||||
| M | 2019-03-12 | BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Coric Vlad | CEO | S - Sale | $50.09 | -100,000 | 2,333,821 | -4% | -$5,008,913 | |||||
| M | 2019-03-13 | VTGN | Vistagen Therapeutics, Inc. | Saxe Jon S | Dir | P - Purchase | $1.26 | +20,000 | 23,251 | +615% | +$25,288 | |||||
| M | 2019-03-12 | CARA | Cara Therapeutics, Inc. | Menzaghi Frederique Ph.D. | Chief Scientific Off,SVP-R, D | S - Sale | $18.65 | -20,000 | 122,779 | -14% | -$373,020 | |||||
2019-03-13 | ABT | Abbott Laboratories | Bird Roger | SVP | S - Sale | $79.06 | -9,188 | 59,807 | -13% | -$726,416 | ||||||
| M | 2019-03-08 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.02 | +21,000 | 21,814,123 | 0% | +$413 | |||||
2019-03-13 | XCUR | Exicure, Inc. | Mirkin Chad A. | Dir, 10% | P - Purchase | $2.50 | +2,200 | 11,299,260 | 0% | +$5,500 | ||||||
2019-03-14 | ESPR | Esperion Therapeutics, Inc. | Mayleben Timothy M | Pres, CEO | P - Purchase | $48.73 | +5,000 | 51,163 | +11% | +$243,650 | ||||||
2019-03-12 | ESPR | Esperion Therapeutics, Inc. | Newton Roger S | Dir | S - Sale | $50.06 | -25,000 | 548,726 | -4% | -$1,251,500 | ||||||
| DM | 2019-03-11 | ATNX | Athenex, Inc. | Zhang Song-Yi | Dir | S - Sale+OE | $11.88 | -120,053 | 5,197,668 | -2% | -$1,425,830 | |||||
2019-03-13 | OCUL | Ocular Therapeutix, Inc | Lindstrom Richard L Md | Dir | P - Purchase | $4.33 | +56,441 | 100,000 | +130% | +$244,390 | ||||||
| D | 2019-03-13 | ATNX | Athenex, Inc. | Trainor-Degirolamo Sheldon | Dir | S - Sale+OE | $11.77 | -45,915 | 665,418 | -6% | -$540,420 | |||||
| D | 2019-03-13 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $93.42 | -3,000 | 510,042 | -1% | -$280,253 | |||||
2019-03-14 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | White Barbara | Chief Medical Officer | P - Purchase | $6.47 | +4,638 | 184,159 | +3% | +$29,994 | ||||||
2019-03-14 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Moran Sean F. | CFO | P - Purchase | $6.67 | +1,500 | 349,510 | 0% | +$10,005 | ||||||
2019-03-14 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO | P - Purchase | $6.49 | +1,530 | 63,190 | +2% | +$9,930 | ||||||
| D | 2019-03-12 | TEVA | Teva Pharmaceutical Industries Ltd | Stark David Matthew | EVP GC | S - Sale+OE | $15.82 | -2,444 | 2,974 | -45% | -$38,664 | |||||
| D | 2019-03-12 | TEVA | Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | S - Sale+OE | $15.67 | -738 | 1,388 | -35% | -$11,568 | |||||
| D | 2019-03-12 | TEVA | Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, Growth Markets Commercial | S - Sale+OE | $15.69 | -325 | 8,450 | -4% | -$5,099 | |||||
| D | 2019-03-12 | TEVA | Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | S - Sale+OE | $15.67 | -953 | 0 | -100% | -$14,938 | |||||
| D | 2019-03-12 | TEVA | Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing, Portfoli | S - Sale+OE | $15.67 | -647 | 8,602 | -7% | -$10,142 | |||||
| D | 2019-03-12 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, European Commercial | S - Sale+OE | $15.69 | -715 | 0 | -100% | -$11,218 | |||||
| DM | 2019-03-12 | ANIP | Ani Pharmaceuticals Inc | Schrepfer Robert W | SVP - New Bus Dev, Spec Sales | S - Sale+OE | $64.44 | -11,796 | 47,842 | -20% | -$760,168 | |||||
2019-03-12 | DRRX | Durect Corp | Arenberg Michael | CFO | P - Purchase | $0.80 | +10,000 | 24,426 | +69% | +$7,990 | ||||||
| DM | 2019-03-11 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $90.06 | -9,000 | 510,042 | -2% | -$810,550 | |||||
2019-03-08 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.36 | +1,000 | 6,773,360 | 0% | +$360 | ||||||
2019-03-11 | ELAN | Elanco Animal Health Inc | Urbanek David Alan | See Remarks | P - Purchase | $0.00 | +2,021 | 14,000 | +17% | +$0 | ||||||
| M | 2019-03-11 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $11.55 | -25,045 | 2,841,029 | -1% | -$289,317 | |||||
2019-03-11 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Presiident, CEO, Dir | P - Purchase | $0.00 | +37,301 | 129,538 | +40% | +$0 | ||||||
2019-03-11 | ELAN | Elanco Animal Health Inc | Schacht Aaron L | See Remarks | P - Purchase | $0.00 | +1,227 | 13,924 | +10% | +$0 | ||||||
2019-03-11 | ELAN | Elanco Animal Health Inc | Kinard David S | See Remarks | P - Purchase | $0.00 | +7,977 | 22,569 | +55% | +$0 | ||||||
2019-03-11 | ELAN | Elanco Animal Health Inc | Cabral Ramiro Martin | See Remarks | P - Purchase | $0.00 | +1,227 | 12,741 | +11% | +$0 | ||||||
2019-03-11 | ELAN | Elanco Animal Health Inc | Hoover R David | Dir | P - Purchase | $0.00 | +920 | 12,716 | +8% | +$0 | ||||||
| M | 2019-03-11 | AKAO | Achaogen, Inc. | Duggan Robert W | 10% | S - Sale | $0.60 | -2,354,007 | 7,035,727 | -25% | -$1,422,348 | |||||
2019-03-11 | EBS | Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | S - Sale | $56.93 | -2,430 | 32,240 | -7% | -$138,340 | ||||||
| M | 2019-02-25 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres | P - Purchase | $0.02 | +56,000 | 26,759,897 | 0% | +$1,151 | |||||
2019-03-13 | VERU | Veru Inc. | Fisch Harry | Dir, 10% | P - Purchase | $1.47 | +3,500 | 8,072,121 | 0% | +$5,145 | ||||||
2019-03-12 | ZTS | Zoetis Inc. | Chen Heidi C. | EVP | S - Sale | $95.49 | -15,710 | 13,963 | -53% | -$1,500,148 | ||||||
2019-03-12 | NATR | Natures Sunshine Products Inc | Wynnefield Partners Small Cap Value LP | 10% | P - Purchase | $9.52 | +5,834 | 2,217,709 | 0% | +$55,517 | ||||||
2019-03-12 | FLXN | Flexion Therapeutics Inc | Clayman Michael D. | Pres, CEO | P - Purchase | $12.36 | +4,046 | 798,205 | +1% | +$50,009 | ||||||
2019-03-11 | CALA | Calithera Biosciences, Inc. | Orford Keith | Chief Medical Officer | S - Sale | $6.00 | -1,565 | 11,249 | -12% | -$9,390 | ||||||
2019-03-11 | APLS | Apellis Pharmaceuticals, Inc. | Morningside Venture Investments Ltd | 10% | P - Purchase | $17.00 | +441,176 | 12,015,802 | +4% | +$7,499,992 | ||||||
2019-03-12 | LLY | Lilly Eli & Co | Fry Stephen F | SVP, HR, Diversity | S - Sale | $123.16 | -14,847 | 109,835 | -12% | -$1,828,557 | ||||||
| A | 2018-11-14 | MNKD | Mannkind Corp | Tross Stuart A | EVP, Chief People Officer | P - Purchase | $1.77 | +14,124 | 77,084 | +22% | +$24,999 | |||||
| A | 2018-11-14 | MNKD | Mannkind Corp | Kendall David M | Chief Medical Officer | P - Purchase | $1.77 | +2,824 | 2,824 | New | +$4,998 | |||||
| A | 2018-11-14 | MNKD | Mannkind Corp | McCauley Patrick | Chief Commercial Officer | P - Purchase | $1.77 | +14,124 | 45,165 | +46% | +$24,999 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |